Promedior Presents Clinical Data for PRM-151 (rhPTX-2) in Idiopathic Pulmonary Fibrosis at American Thoracic Society 2011  
5/16/2011 12:05:36 PM

MALVERN, Pa.--(BUSINESS WIRE)--Promedior, Inc., a clinical stage biotechnology company developing novel therapies to treat fibrotic and inflammatory diseases, presented data from a clinical study of PRM-151 (recombinant human Pentraxin-2 (PTX-2)) at the 2011 American Thoracic Society International Conference (ATS 2011). The poster presentation entitled ”The Effects Of Recombinant Human Pentraxin-2, (PRM-151), On Circulating Fibrocytes In Idiopathic Pulmonary Fibrosis (IPF)” included clinical data from a completed Phase 1 study of PRM-151 that evaluated comprehensive safety endpoints and exploratory biomarker activity in healthy subjects and IPF patients. Across all study participants, PRM-151 was shown to be generally safe and well tolerated; and in a subset of study participants with IPF, PRM-151 showed activity against efficacy biomarkers through reductions in IPF-related blood fibrocytes levels and serum IL-6 levels.